CDMO giant Catalent inked a deal with Sarepta Therapeutics to manufacture what looks to become the first gene therapy to treat Duchenne muscular dystrophy (DMD). In November, the FDA gave its ...

After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...

Under the agreement, Santhera will receive an initial payment of $40m from Nxera.

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered acute ...

Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...

Ifetroban significantly improved LVEF in DMD patients, showing a 5.4% improvement compared with propensity-matched natural history controls, with high-dose treatment yielding the most benefit. The ...

Adult men with DMD have over twice the fracture risk compared to non-DMD counterparts, with corticosteroids increasing this risk further. Bone health monitoring is inadequate, with less than half of ...

DMD Systems Recovery, LLC (DMD), a Reuse First® IT Asset Disposition (ITAD) provider and Certified B Corporation, has earned its third consecutive recognition on the Real Leaders® Top Impact Companies ...